Aprineon 125mg/80mg Capsule (Aprepitant)
Prescription RequiredManufactured By
Neon
Pack Of
3
Salt Composition
Aprepitant
Storage
Keep in cold place
ALL SUBSTITUTES
Aprepit 125mg Capsule
Apremac Capsule
Aprecap Capsule
Apretero Capsule
Aprepit 125mg/80mg Capsule
Prepit Capsule
Overview
Aprineon 125mg/80mg Capsule contains Aprepitant, a salt composition which is a neurokinin-1 (nk1) receptor antagonist. Prevention of acute and delayed chemotherapy-induced nausea and vomiting with a 5-HT3 antagonist and corticosteroid. It is preventive, not a rescue treatment for established vomiting.
Aprepitant 125mg capsule blocks substance P binding to NK1 receptors in central emetic pathways. Its action complements serotonin 5-HT3 blockade and corticosteroid therapy. The exact strength and presentation matter for safe dosing; patients should follow the treating specialist’s plan and should not substitute a different strength or formulation without review.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | aprineon |
| Generic / Active Ingredient | Aprepitant |
| Strength | 125 |
| Dosage Form | Capsule |
| Manufacturer / Marketer | neon |
| Pack Size | 3 |
| Prescription Required | Yes |
| Therapeutic Categories | Cancer Medicines |
| Uses | Nausea and Vomiting |
Uses and Indications
Aprineon 125mg capsule are administered with other antiemetic drugs in order to prevent the following:
- Acute nausea and vomiting in case of highly emetogenic chemotherapy.
- Delayed nausea and vomiting that may arise following chemotherapy.
- Nausea and vomiting from moderately emetogenic chemotherapy.
The standard therapy involves the administration of aprepitant capsule along with 5-HT3 receptor antagonists and corticosteroids, depending upon the chemotherapy schedule and treatment plan of the individual. Aprepitant 125mg is used only as a preventive measure and not to treat nausea and vomiting.
How Aprineon 125mg/80mg Capsule Works
Aprepitant 125mg capsule is an NK1 receptor antagonist. While undergoing chemotherapy, some signals within the brain can initiate the emesis pathway. Substances such as substance P play a role in this pathway. Aprepitant 125mg works by preventing substance P from attaching to NK1 receptors. It aids in reducing signals that cause nausea and vomiting. Its mechanism works well alongside 5-HT3 receptor blockers and corticosteroids in antiemetic therapy.
Clinical Evidence for Aprineon 125mg/80mg Capsule
- There is clinical evidence to suggest that the addition of aprepitant capsule to regular antiemetics would help achieve better management of nausea and vomiting caused by chemotherapy compared with regular antiemetic drugs alone.
- The therapeutic effect achieved depends upon the total antiemetic drug regimen, which includes aprepitant 125mg, a 5-HT3 antagonist, and a corticosteroid. Hence, it cannot be concluded from the above-mentioned clinical results that Aprineon 125mg capsule was therapeutically effective.
Side Effects of Aprineon 125mg/80mg Capsule
These side effects may be experienced by some people:
- Fatigue
- Hiccup
- Constipation
- Indigestion
- Headache
- Diarrhoea
- Abdominal pain
- Loss of appetite
- Weakness
All these side effects do not happen to all patients. Any patient experiencing any of these symptoms constantly must discuss with their healthcare provider.
Critical Safety Warning
- Aprepitant 125mg capsule might induce rarely occurring hypersensitivity reactions like allergic reactions. If you notice any difficulties with breathing or swallowing, severe rashes, hives, itching, or skin peeling, seek emergency medical assistance immediately.
- Aprepitant capsule affects the CYP3A4 enzyme system, and there may be changes in concentration or activity of other drugs. Some combinations of aprepitant capsule with other drugs are contraindicated; others need adjustments or observation.
- The efficacy of hormone-based contraception methods may be decreased with aprepitant 125mg. Choose another type of contraception for the whole period of treatment and 28 days after the end of the therapy.
- Aprepitant 125mg capsule may decrease the action of warfarin in some patients. INR should be measured within two weeks after the end of the therapy, especially 7 to 10 days after its start.
Aprineon 125mg/80mg Capsule Dosage and How To Take It
| Clinical situation | Dose |
|---|---|
| Unit strength | 125mg orally about 1 hour before chemotherapy |
| Administration | Day 1: 125mg by mouth about one hour before chemotherapy; Days 2 and 3: 80mg once each morning, or about one hour before chemotherapy if scheduled. Swallow capsules whole, with or without food. The kit contains separate capsules, not a single 205mg capsule. |
| Route | Oral |
| Dose changes | Only on the treating clinician’s instructions. |
Aprineon 125mg/80mg Capsule Missed Dose
Contact the treating team or consult the exact product leaflet for timing-specific advice. Do not double the next dose. Since aprepitant capsule is given based on the schedule of chemotherapy administration, missing a dose will require assessment of when the dose was missed.
Safety Advice for Aprineon 125mg/80mg Capsule
| Category | Status | Guidance |
|---|---|---|
| Pregnancy / Breastfeeding | Requires Medical Advice | Consult with the treating health care provider about pregnancy, pregnancy planning, or breast-feeding before starting treatment. |
| Liver / Kidney Function | Requires Assessment | Let the physician know about any liver disease. Adjustment of dose usually is unnecessary in mild-to-moderate hepatic impairment and renal impairment including hemodialysis; however, there is inadequate information regarding severe hepatic impairment. |
| Interactions | Needs Review | Let the health care providers know about any prescription drugs, over-the-counter drugs, nutritional supplements, and herbal products. INR testing might be needed if using warfarin, and other contraceptive methods apart from hormonal contraceptives might be required. |
| Monitoring | Required Where Appropriate | INR testing might be required following aprepitant 125mg use, especially in those patients using warfarin. |
| Self-Adjustment | Not Recommended | Avoid changing or discontinuing the antinausea drug regimen without consulting the doctor. |
Monitoring During Aprineon 125mg/80mg Capsule Treatment
Possible monitoring includes:
- Evaluation of the chemotherapy regimen.
- Evaluation of the other antiemetic drugs that are co-administered along with aprepitant capsule.
- Drug-drug interaction evaluation.
- Evaluation of the management of nausea and vomiting.
- Hydration evaluation if the patient experiences vomiting.
- INR monitoring in patients on warfarin therapy.
- Evaluation of any allergic or hypersensitive reactions.
This drug interacts with many other drugs; hence the entire drug regimen needs to be evaluated before administration.
Aprineon 125mg/80mg Capsule Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Molecule | Aprepitant |
| Strength | 125mg capsule × 1 and 80mg capsule × 2 |
| Dosage form | Oral hard capsules supplied as a three-day kit |
| Class | Neurokinin-1 (NK1) receptor antagonist |
| Uses | Prevention of chemotherapy-induced nausea and vomiting. |
| How to take | 125mg on Day 1 and 80mg on Days 2 and 3 |
| Key warning | Serious hypersensitivity; clinically important CYP3A4 interactions; reduced hormonal contraceptive effectiveness; altered INR with warfarin. |
Aprineon 125mg/80mg Capsule Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Pimozide | Severe heart effects | Not to be used with aprepitant 125mg because of raised pimozide levels. |
| Dexamethasone | Increased exposure | Steroids may require dose modification. |
| Certain chemotherapy medicines | Drug level changes | Evaluate chemotherapy regimen for potential interaction involving CYP3A4. |
| Warfarin | Decreased anticoagulant effect | Monitor INR following aprepitant 125mg capsule administration as recommended. |
| Hormonal contraceptives | Decreased effectiveness | An extra non-hormonal method of contraception should be used while on therapy and for 28 days thereafter. |
| Other CYP3A4 medicines | Drug level changes | Dosage modification may be necessary. |
FAQs About Aprineon 125mg/80mg Capsule
What is the full name of Aprineon capsule?
Aprineon 125mg/80mg Capsule Kit is the complete name of the medicine with its active component called "Aprepitant".
What is Aprineon capsule exact strength?
125mg capsule × 1 and 80mg capsule × 2 is the complete strength of Aprepitant 125mg.
What dosage form is it?
Oral hard capsules supplied as a three-day kit
What is Aprepitant 125mg capsule used for?
Prevention of acute and delayed chemotherapy-induced nausea and vomiting with a 5-HT3 antagonist and corticosteroid. Aprepitant capsule is preventive, not a rescue treatment for established vomiting.
How does Aprineon 125mg capsule work?
Aprepitant 125mg capsule blocks substance P binding to NK1 receptors in central emetic pathways. Its action complements serotonin 5-HT3 blockade and corticosteroid therapy.
How is Aprineon capsule taken?
Day 1: 125mg by mouth about one hour before chemotherapy; Days 2 and 3: 80mg once each morning, or about one hour before chemotherapy if scheduled. Swallow capsules whole, with or without food. The kit contains separate capsules, not a single 205mg capsule.
What are common side effects of Aprepitant 125mg?
Fatigue, hiccups, constipation, dyspepsia, headache and reduced appetite are some of the common side effects of Aprepitant capsule.
What are the serious warnings?
Serious hypersensitivity; clinically important CYP3A4 interactions; reduced hormonal contraceptive effectiveness; altered INR with warfarin.
What tests or checks are needed?
Review chemotherapy schedule, concomitant dexamethasone dose, drug interactions, vomiting control and hydration; check INR after treatment in patients on warfarin.
Can I substitute a similar medicine?
Only after a clinician/pharmacist verifies ingredient, strength, dosage form and dosing schedule.
References
- DailyMed. Aprepitant Capsules – Prescribing Information. U.S. National Library of Medicine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d72e0e10-4557-41b0-b65d-d395468cad19
- U.S. Food and Drug Administration (FDA). EMEND (Aprepitant) Capsules – Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021549s014lbl.pdf
- American Society of Clinical Oncology (ASCO). Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology https://ascopubs.org/doi/10.1200/JCO.20.01296?referrer=https%3A%2F%2Fwww.google.com%2F
- Multinational Association of Supportive Care in Cancer (MASCC) / European Society for Medical Oncology (ESMO). MASCC/ESMO Antiemetic Guidelines – 2023 Update https://www.esmoopen.com/article/S2059-7029(23)01436-9/fulltext
- National Cancer Institute (NCI). Nausea and Vomiting and Cancer Treatment https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting
Marketer Details
Neon
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
